Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial

On behalf of the Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer), A. Santo, S. Pilotto, D. Galetta, F. Grossi, G. Fasola, G. Romano, L. Bonanno, A. Bearz, M. Papi, E. Roca, A. Catino, A. Follador, E. Rijavec, C. Genova, P. Petrillo, A. Favaretto, L. Giannone, M. Milella, G. TortoraD. Giannarelli, E. Bria

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)121-126
Number of pages6
JournalLung Cancer
Publication statusPublished - 2019


  • Lanreotide
  • Maintenance
  • Small-cell lung cancer
  • Somatostatine analogue
  • angiopeptin
  • somatostatin receptor
  • abdominal pain
  • adult
  • adverse outcome
  • aged
  • Article
  • cancer chemotherapy
  • cancer growth
  • cancer radiotherapy
  • cancer staging
  • controlled study
  • disease severity
  • drug efficacy
  • drug safety
  • electrolyte disturbance
  • female
  • human
  • maintenance therapy
  • major clinical study
  • male
  • multicenter study
  • overall survival
  • phase 3 clinical trial
  • predictor variable
  • priority journal
  • progression free survival
  • protein expression
  • randomized controlled trial
  • small cell lung cancer
  • treatment duration
  • treatment response

Cite this